N,S-dimethyl-S-(4-methoxyphenyl)sulfoximine | 67087-51-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N,S-dimethyl-S-(4-methoxyphenyl)sulfoximine
• 英文别名: [(4-methoxyphenyl)(methyl)oxo-λ⁶-sulfanylidene](methyl)amine；5-(p-Methoxyphenyl)-N,S-dimethylsulfoximin；[(4-Methoxyphenyl)(methyl)oxo-lambda6-sulfanylidene](methyl)amine；(4-methoxyphenyl)-methyl-methylimino-oxo-λ6-sulfane
• CAS: 67087-51-8
• 化学式: C₉H₁₃NO₂S
• 分子量: 199.274
• InChiKey: MWFDWIAWKIUIDF-UHFFFAOYSA-N

物化性质

• 沸点：
  311.1±44.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  47
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N,S-dimethyl-S-(4-methoxyphenyl)sulfoximine 在 次氯酸叔丁酯 、 potassium carbonate 作用下， 以 二氯甲烷 为溶剂， 生成 S-Chlormethyl-S-p-anisyl-N-methyl-sulfoximin
  参考文献：
  名称：

  Preparation of .alpha.-halo sulfoximines

  摘要：

  DOI：

  10.1021/jo00415a033
• 作为产物：
  描述：

  在 potassium permanganate 、 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 16.0h， 以114 mg的产率得到N,S-dimethyl-S-(4-methoxyphenyl)sulfoximine
  参考文献：
  名称：

  Direct Access to N-Alkylsulfoximines from Sulfides by a Sequential Imidation/Oxidation Procedure

  摘要：

  Synthetically relevant N-alkyl-substituted sulfoximines are directly prepared from sulfides by an unprecedented one-pot imidation/oxidation sequence. In situ generated N-bromoalkylamines serve as readily accessible imidating agents leading to N-alkylsulfiliminium bromides that are subsequently oxidized providing the corresponding N-alkylsulfoximines. In this manner, gram quantities of the products can be obtained in a short period of time avoiding the use of toxic and cumbersome to handle alkylating reagents.

  DOI：

  10.1055/s-0034-1380536

文献信息

• JOHNSON C. R.; CORKINS H. G., J. ORG. CHEM., 1978, 43, NO 21 4136-4140
  作者：JOHNSON C. R.、 CORKINS H. G.

  DOI：——

  日期：——
• [EN] APOL1 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS D'APOL1 ET MÉTHODES D'UTILISATION
  申请人：[en]MAZE THERAPEUTICS, INC.

  公开号：WO2023141432A2

  公开（公告）日：2023-07-27

  Provided herein are compounds of formula (II): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, whereinm, n, p, R1, R2, R3, L1, L2, L3, R4, X1, X2, X3, and X4are as defined herein. Also provided are methods of preparing compounds of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods of inhibiting APOL1 and methods of treating an APOL1 -mediated disease, disorder, or condition in an individual.